Friulimicin B

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameFriulimicin B
Drug Alias NameFriulimicinLipopeptide Merlion PharmaceuticalsA-1437D
ClassificationSmall molecules > Heterocyclic drugs > AntibioticsNatural product/ExtractSmall molecules > Synthetic peptide
Mechanisms of ActionCell wall inhibitors
TargetsNot applicable
Therapy Area/IndicationsCommunity Acquired PneumoniaStaphylococcal Skin Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerlion Pharmaceuticals Gmbh
Active IndicationsN/A
Inactive IndicationsCommunity Acquired PneumoniaStaphylococcal Skin Infections

Other Information

ATC CodeN/A
Related LinksN/A